Resource Logo
Being Alive



Being Alive 1993 Feb 5: 10

Researchers and clinicians will be analyzing the full reports and discussing the implications in clinical practice. Early thinking is that the 116A results will confirm AZT as the first choice nucleoside drug for monotherapy in new patients. Those for whom AZT does not seem to be working or who have major adverse reactions will probably be encouraged to consider ddI as an early alternative. The FDA will probably swiftly move to expand ddC's approved indications (currently only for combination therapy with AZT) to include it as a monotherapy alternative to ddI for those who fail on or cannot tolerate AZT.

Anyone currently taking or considering taking any of these three drugs should, as always, consult carefully with your medical care provider to discuss which drug or combination has the best estimated benefit/risk ratio in your individual case. 


Information in this article was accurate in February 5, 1993. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.